Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

33%(1 trials)

Phase Distribution

Ph phase_1

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution1 total trials

Phase 1Safety & dosage

1(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Phase 11 (100.0%)

Trials by Status

completed3100%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_1

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

NCT03258593

completed

Changes of microRNA Expression in Obstructive and Neurogenic Bladder Dysfunction

NCT02410876

completed

Multi Center Study to Obtain Bladder Tissue Specimens From Patients Undergoing Transurethral Resection Biopsy Procedure

NCT00615043

Clinical Trials (3)

Showing 3 of 3 trials

NCT03258593Phase 1

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Completed

NCT02410876

Changes of microRNA Expression in Obstructive and Neurogenic Bladder Dysfunction

Completed

NCT00615043

Multi Center Study to Obtain Bladder Tissue Specimens From Patients Undergoing Transurethral Resection Biopsy Procedure

Completed

All 3 trials loaded

Drug Details

Intervention Type: PROCEDURE
Total Trials: 3